The goal of this observational study, is to improve the diagnostic assessment method of malnutrition and kidney diseases, amongst hospitalized and low priority patients, by evaluating modern methodology and biomarkers, with regards to an estimate of the nutritional status and kidney diseases, against current gold standards, and also investigate how body composition, hydration, inflammation and age affect the assessments.
Eligibility
Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* 65 years or older (group 1, 4 and 5)
* 90 years or older (group 3)
* Acute admission (group 1, 2)
* Cognitively able to cooperate (group 1)
* Able to read and speak Danish (group 1, 2, 3, 4, 5, 6)
* BMI ≥ 35 kg/m2 (group 4)
* Prednisolon treatment for COPD (≥ 37,5 mg daily) (group 5)
* Amputation(s) of crus or femur (non-traumatic) (group 6)
Exclusion Criteria:
* Isolation (group 1, 2, 3, 4, 5, 6)
* Terminal treatment (group 1, 2, 3, 4, 5, 6)
* Suicidal (group 1, 2, 3, 4, 5, 6)
* Active Immune suppressing treatment (group 2, 3, 4, 5, 6)
* Oedemas (group 2, 3, 4, 5, 6)
* In active treatment for cancer (group 2, 3, 4, 5, 6)
Primary outcome measure(s)
To investigate whether the method used to determine body composition affects the diagnosis of malnutrition when applying the GLIM criteria. — Time of inclusion and/or 14 days after preliminary inclusion. This will be conducted via BIA- and DXA-scans and with the use of GLIM criteria
To evaluate the performance of eGFR based on creatinine, cystatin C, B2M, and BTP relative to mGFRDBS in acutely hospitalized patients with a cystatin C/kreatinin ratio <0,7 (patients from groups 1 and 2) — From enrollment to 6-8 hours later same day (when mGFRDBS is completed) mGFRDBS will be performed and the biomarkers will be analyzed afterwards for making this analysis
To evaluate the performance of eGFR based on creatinine, cystatin C, B2M, and BTP relative to mGFRDBS in patients aged ≥90 år (patients from groups 1 and 3) — From enrollment to 6-8 hours later same day (when mGFRDBS is completed) mGFRDBS will be performed and the biomarkers will be analyzed afterwards for making this analysis
To evaluate the performance of eGFR based on creatinine, cystatin C, B2M, and BTP relative to mGFRDBS in patients with BMI ≥35 kg/m2 (patients from groups 1 and 4) — From enrollment to 6-8 hours later same day (when mGFRDBS is completed) mGFRDBS will be performed and the biomarkers will be analyzed afterwards for making this analysis
To determine changes in mGFRDBS during and after treatment with ≥37.5 mg daily prednisolone (patients from group 5) — From enrollment to approximately 10-35 days after prednisolone treatment mGFRDBS will be performed twice
To determine changes in mGFRDBS before and after amputation (patients from group 6) — From enrollment to follow-up after amputation (approximately 3 weeks after operation) mGFRDBS will be performed twice
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.